# Servier

Source: https://onco.cc/companies/servier/  
OnCo record `servier` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Servier is the private French pharma that brought vorasidenib, the first low-grade glioma drug, to market.

## Summary

Servier is the private French pharmaceutical company, based in Suresnes, that brought vorasidenib, the first drug for IDH-mutant low-grade glioma, to market. Vorasidenib and ivosidenib, sold as Tibsovo, came from its acquisition of the Agios oncology business, and OnCo links it to the INDIGO paper on vorasidenib, to AGILE on ivosidenib plus azacitidine in IDH1-mutated acute myeloid leukaemia, to NAPOLI-3 and trifluridine and tipiracil in gastrointestinal cancer, to asparaginase products and to the UCART19 gene-edited CAR-T paper. The brain as a barrier and sanctuary is the bottleneck vorasidenib was designed to cross. How long IDH inhibition can defer radiotherapy and chemotherapy in low-grade glioma is the open question. Vorasidenib has its own page.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- HQ: Suresnes
- Type: pharma
- Website: https://servier.com

## Sources

- Official website: https://servier.com

## Connected records

- fronts: [Epigenetic & Transcriptional Therapy](https://onco.cc/fronts/epigenetics/)
- drugs: [Asparaginase (pegaspargase, calaspargase pegol, Erwinia asparaginase)](https://onco.cc/drugs/asparaginase/), [Ivosidenib](https://onco.cc/drugs/ivosidenib/), [Liposomal irinotecan](https://onco.cc/drugs/liposomal-irinotecan/), [Pixantrone](https://onco.cc/drugs/pixantrone/), [TNG462](https://onco.cc/drugs/tng462/), [Trifluridine/tipiracil](https://onco.cc/drugs/trifluridine-tipiracil/), [Vorasidenib](https://onco.cc/drugs/vorasidenib/)
- trials: [AGILE](https://onco.cc/trials/agile/), [An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma](https://onco.cc/trials/nct05876754/), [An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.](https://onco.cc/trials/nct05907057/), [BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients](https://onco.cc/trials/nct07071844/), [INDIGO](https://onco.cc/trials/indigo/), [Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen](https://onco.cc/trials/nct06127407/), [Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct06162572/), [RECOURSE](https://onco.cc/trials/recourse/), [Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer](https://onco.cc/trials/nct06245356/), [SUNLIGHT](https://onco.cc/trials/sunlight/)
- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Astrocytoma, IDH-mutant (grades 2 to 4)](https://onco.cc/cancers/idh-mutant-astrocytoma/), [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- key papers: [AGILE: ivosidenib plus azacitidine for newly diagnosed IDH1-mutated AML in patients unfit for intensive chemotherapy](https://onco.cc/key-papers/paper-agile-ivosidenib-azacitidine-nejm-2022/), [INDIGO: vorasidenib, the first targeted drug for IDH-mutant low-grade glioma](https://onco.cc/key-papers/paper-indigo-nejm-2023/), [NAPOLI-3: NALIRIFOX versus gemcitabine plus nab-paclitaxel as first treatment for metastatic pancreatic cancer](https://onco.cc/key-papers/paper-napoli-3-lancet-2023/), [Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer (SUNLIGHT)](https://onco.cc/key-papers/paper-prager-sunlight-trifluridine-tipiracil-bevacizumab-nejm-2023/), [UCART19: the first gene-edited, donor-derived CAR-T cells in children and adults with relapsed B-cell ALL](https://onco.cc/key-papers/paper-ucart19-allogeneic-car-t-lancet-2020/)
- roadmaps: [Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation](https://onco.cc/roadmaps/colorectal-roadmap/)
- bottlenecks: [The brain: barrier and sanctuary](https://onco.cc/bottlenecks/b-brain-delivery/)

---
JSON: https://onco.cc/api/v1/entities/servier.json